Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study - Concepedia

Concepedia

Publication | Open Access

Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study

DOI Full Paper Access

40

Citations

24

References

2023

Year

Alix Miauton, R Audran, Juliette Besson, Hélène Maby–El Hajjami, Maxime Karlen, Loane Warpelin‐Decrausaz, Loredana Sene, Sylvain Schaufelberger, Vincent Faivre, Mohamed Faouzi,

Abstract

Emergex Vaccines Holding Limited.

References

	Year	Citations

Page 1